TherapeuticsMD (TXMD) Cash from Investing Activities (2011 - 2022)
TherapeuticsMD's (TXMD) quarterly Cash from Investing Activities came in at -$74000.0 in Q4 2022, up 95.11% on a YoY basis from -$37926.9 in Q4 2021, and down 1157.14% quarter-over-quarter from $7000.0 in Q3 2022.
Powered by 
Analysis
TherapeuticsMD (TXMD) Cash from Investing Activities (2011 - 2022) Analysis & Trends
TherapeuticsMD (TXMD) has reported Cash from Investing Activities for 12 consecutive years, with -$74000.0 the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Cash from Investing Activities rose 95.11% year-over-year to -$74000.0; the trailing twelve-month figure through Dec 2022 stood at -$355000.0 (up 84.03% YoY), and the FY2022 full-year result was -$355000.0, up 84.03% from the prior year.
- Cash from Investing Activities slipped to -$74000.0 in Q4 2022 per TXMD's latest filing, from $7000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $7000.0 in Q3 2022 and bottomed at -$20.7 million in Q4 2019.
- Historically, Cash from Investing Activities has averaged -$2.5 million across 5 years, with a median of -$418500.0 in 2020.
- The sharpest annual moves came in 2018 and 2022: Cash from Investing Activities sank 28077.04% in 2018, then surged 103.85% in 2022.
- Over 5 years, Cash from Investing Activities stood at -$671171.0 in 2018, then tumbled by 2986.19% to -$20.7 million in 2019, then soared by 97.62% to -$494000.0 in 2020, then plunged by 206.48% to -$1.5 million in 2021, then surged by 95.11% to -$74000.0 in 2022.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$74000.0, $7000.0, and -$76000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -1.61 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -424.26 Mn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | -1.66 Bn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | -49.35 Mn |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -74,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | -76,000.00 |
| Mar 31, 2022 | -212,000.00 |
| Dec 31, 2021 | -1.51 Mn |
| Sep 30, 2021 | -182,000.00 |
| Jun 30, 2021 | -89,000.00 |
| Mar 31, 2021 | -438,000.00 |
| Dec 31, 2020 | -494,000.00 |
| Sep 30, 2020 | -262,000.00 |
| Jun 30, 2020 | -399,000.00 |
| Mar 31, 2020 | -443,000.00 |
| Dec 31, 2019 | -20.71 Mn |
| Sep 30, 2019 | -1.30 Mn |
| Jun 30, 2019 | -1.21 Mn |
| Mar 31, 2019 | -665,914.00 |
| Dec 31, 2018 | -671,171.00 |
| Sep 30, 2018 | -20.33 Mn |
| Jun 30, 2018 | -311,353.00 |
| Mar 31, 2018 | -180,530.00 |